Progress and Challenges of the New Conditional Approval Process in China: A Pooled Analysis From 2018 to 2021-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Progress and Challenges of the New Conditional Approval Process in China: A Pooled Analysis From 2018 to 2021

Published:2023-11 Issue:11 Volume:45 Page:1111-1118
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Li Jinlian^ORCID,Wang Haoyang,Hua Yanzhao,Liu Yue,Chen Yi,Jiang Rong,Shao Rong,Xie Jinping

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference33 articles.

1. INSIGHT. How long does it take to review a drug? 2014. http://yao.dxy.cn/article/92630.1. Accessed September 28, 2022.

2. Center for Drug Evaluation. Annual Drug Review Report 2015. https://www.cde.org.cn/main/news/viewInfoCommon/962da6d54695d4f2f91faef72d1b6776. 2016. Accessed September 28, 2022.

3. The new drug conditional approval process in China: challenges and opportunities;Yao;Clin Ther,2017

4. Progress of China's priority review system for drug registration and related considerations;Gao;Chin New Drugs J,2017

5. Deepening the reform of review and approval system to promote high-quality development of pharmaceutical products;Kong;Chin Food and Drug Admin,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP